Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus
Autore:
Verschoor, EJ; Davis, D; van Gils, M; Koopman, G; Mooij, P; Oostermeijer, H; Ten Haaft, P; Verstrepen, B; Rosenwirth, B; Morein, B; Barnett, SW; Heeney, JL;
Indirizzi:
Biomed Primate Res Ctr, Dept Virol, NL-2280 GH Rijswijk, Netherlands Biomed Primate Res Ctr Rijswijk Netherlands NL-2280 GH wijk, Netherlands Inst Trop Med, Dept Microbiol, Virol Unit, Antwerp, Belgium Inst Trop MedAntwerp Belgium t Microbiol, Virol Unit, Antwerp, Belgium Natl Vet Inst, Dept Virol, S-75123 Uppsala, Sweden Natl Vet Inst UppsalaSweden S-75123 Dept Virol, S-75123 Uppsala, Sweden Chiron Corp, Emeryville, CA 94608 USA Chiron Corp Emeryville CA USA 94608Chiron Corp, Emeryville, CA 94608 USA
Titolo Testata:
JOURNAL OF MEDICAL PRIMATOLOGY
fascicolo: 4-5, volume: 28, anno: 1999,
pagine: 224 - 232
SICI:
0047-2565(199908/10)28:4-5<224:ETBHIB>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY-TITERS CORRELATE; VACCINE PROTECTION; RHESUS MACAQUES; HIV-1 VACCINE; CYNOMOLGUS MONKEYS; INFECTED MACAQUES; RAPID EVOLUTION; ATTENUATED SIV; TYPE-1;
Keywords:
broadening immunity; AIDS vaccine; rhesus macaque; antigenic sin; live-attenuated effect;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Agriculture,Biology & Environmental Sciences
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Heeney, JL Biomed Primate Res Ctr, Dept Virol, POB 3306, NL-2280 GH Rijswijk, Netherlands Biomed Primate Res Ctr POB 3306 Rijswijk Netherlands NL-2280 GH
Citazione:
E.J. Verschoor et al., "Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus", J MED PRIM, 28(4-5), 1999, pp. 224-232

Abstract

In two previous studies, we have demonstrated the successful protection ofhuman immunodeficiency virus type 1 (HIV-1)-vaccinated rhesus macaques from challenge with SHIVSF13 with envelop immunogens derived from the closely related HIV-1(SF2) strain. Here we report on two follow-up studies in whichwe aimed to broaden immunity in order to elicit protection from a more diverse heterologous challenge with SHIVSF33. In the first study, animals wereboosted once with HIV-1(SF33) V2 and V3 peptides that were cross-linked toinfluenza immune-stimulating complexes (ISCOMs). In the second study, monkeys were boosted twice at 12-week intervals, using a heterologous recombinant gp120 derived from HIV-1(SF33) that was either incorporated into ISCOMs or mixed with the MF59 adjuvant. In both studies, the animals were challenged with 50 monkey infectious doses of SHIVSF33 4 weeks after the final boost. All controls became readily infected with the heterologous challenge virus SHIVSF33. Neither boosting with heterologous SF33 peptides or gp120 afforded protection from infection to SF2-vaccinated animals that had previously resisted SHIVSF13 challenge. These results demonstrate the importance of developing vaccine strategies that are capable of generating broad immune responses early in the immunization protocol. Furthermore, these findings may illustrate the potential pitfalls of early antigenic sin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 16:38:05